CoChat

Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases

Open access
Kalla, Rahul, Kennedy, Nicholas A, Ventham, Nicholas T, Boyapati, Ray K, Adams, Alex T, Nimmo, Elaine R, Visconti, Micaela R, Drummond, Hazel, Ho, Gwo-Tzer, Pattenden, Rebecca J, Wilson, David C, Satsangi, Jack · 2016 · American Journal of Gastroenterology
Cited by 124

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: There is an unmet need for novel blood-based biomarkers that offer timely and accurate diagnostic and prognostic testing in inflammatory bowel diseases (IBD). We aimed to investigate the diagnostic and prognostic utility of serum calprotectin (SC) in IBD. METHODS: A total of 171 patients (n=96 IBD,n=75 non-IBD) were prospectively recruited. A multi-biomarker model was derived using multivariable logistic regression analysis. Cox proportional hazards model was derived to assess the contribution of each variable to disease outcomes. RESULTS: SC correlated strongly with current biomarkers, including fecal calprotectin (FC) (n=50,ρ=0.50,P=1.6 × 10−4). SC was the strongest individual predictor of IBD diagnosis (odds ratio (OR): 9.37 (95% confidence interval (CI): 2.82–34.68),P=4.00 × 10−4) compared with other markers (C-reactive protein (CRP): OR 8.52 (95% CI: 2.75–28.63),P=2.80 × 10−4); albumin: OR 6.12 (95% CI: 1.82–22.16),P=0.004). In a subset of 50 patients with paired SC and FC, the area under receiver operating characteristic discriminating IBD from controls was better for FC than for SC (0.99, (95% CI 0.87–1.00) and 0.87 (95% CI:0.78–0.97), respectively;P=0.01). At follow-up (median 342 days; interquartile range: 88–563), SC predicted treatment escalation and/or surgery in IBD (hazard ratio (HR) 2.7, 95% CI: 1.1–4.9), in particular Crohn’s disease (CD) (HR 4.2, 95% CI 1.2–15.3). A model incorporating SC and either CRP or albumin has a positive likelihood ratio of 24.14 for IBD. At 1 year, our prognostic model can predict treatment escalation in IBD in 65% of cases (95% CI: 43–79%) and 80% (95% CI: 31–94%) in CD if ≥2 blood marker criteria are met. CONCLUSIONS: A diagnostic and prognostic model that combines SC and other blood-based biomarkers accurately predicts the inflammatory burden in IBD and has the potential to predict disease and its outcomes. Our data warrant further detailed exploration and validation in large multicenter cohorts.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ajg.2016.342

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 45

  1. Kalla, 2014, Crohns disease., BMJ, 349, g6670, 10.1136/bmj.g6670 · DOI
  2. Ford, 2013, Ulcerative colitis., BMJ, 346, f432, 10.1136/bmj.f432 · DOI · Paper page
  3. Loftus, 2004, Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences., Gastroenterology, 126, 1504, 10.1053/j.gastro.2004.01.063 · DOI · Paper page
  4. Kappelman, 2007, The prevalence and geographic distribution of Crohns disease and ulcerative colitis in the United States., Clin Gastroenterol Hepatol, 5, 1424, 10.1016/j.cgh.2007.07.012 · DOI · Paper page
  5. Kappelman, 2008, Direct health care costs of Crohns disease and ulcerative colitis in US children and adults., Gastroenterology, 135, 1907, 10.1053/j.gastro.2008.09.012 · DOI · Paper page
  6. Burisch, 2013, The burden of inflammatory bowel disease in Europe., J Crohns Colitis, 7, 322, 10.1016/j.crohns.2013.01.010 · DOI · Paper page
  7. Sands, 2015, Biomarkers of inflammation in inflammatory bowel disease., Gastroenterology, 149, 1275, 10.1053/j.gastro.2015.07.003 · DOI · Paper page
  8. Viennois, 2015, Biomarkers of inflammatory bowel disease: from classical laboratory tools to personalized medicine., Inflamm Bowel Dis, 21, 2467
  9. Kaiser, 2007, Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome., Gut, 56, 1706, 10.1136/gut.2006.113431 · DOI · Paper page
  10. van Rheenen, 2010, Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis., BMJ, 341, c3369, 10.1136/bmj.c3369 · DOI · Paper page
  11. Lehmann, 2015, The role and utility of faecal markers in inflammatory bowel disease., Therap Adv Gastroenterol, 8, 23, 10.1177/1756283X14553384 · DOI
  12. Ho, 2009, Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis., Am J Gastroenterol, 104, 673
  13. Meuwis, 2013, Serum calprotectin as a biomarker for Crohns disease., J Crohns Colitis, 7, e678, 10.1016/j.crohns.2013.06.008 · DOI · Paper page
  14. Lasson, 2014, The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis., J Crohns Colitis, 9, 26
  15. Calafat, 2015, High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm., Bowel Dis, 21, 1072, 10.1097/MIB.0000000000000349 · DOI
  16. Reid, 2015, Measurement of serum calprotectin in stable patients predicts exacerbation and lung function decline in cystic fibrosis., Am J Respir Crit Care Med, 191, 233, 10.1164/rccm.201407-1365LE · DOI
  17. Gray, 2010, Sputum and serum calprotectin are useful biomarkers during CF exacerbation., J Cyst Fibros, 9, 193, 10.1016/j.jcf.2010.01.005 · DOI · Paper page
  18. Abildtrup, 2015, Calprotectin as a biomarker for rheumatoid arthritis: a systematic review., J Rheumatol, 42, 760, 10.3899/jrheum.140628 · DOI
  19. Obry, 2014, Identification of S100A9 as biomarker of responsiveness to the methotrexateetanercept combination in rheumatoid arthritis using a proteomic approach., PLoS One, 9, e115800, 10.1371/journal.pone.0115800 · doi:10.1371/journal.pone.0115800
  20. Mariani, 2014, Serum calprotectin: review of its usefulness and validity in paediatric rheumatic diseases., Clin Exp Rheumatol, 33, 109
  21. Hammer, 2010, Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis., Ann Rheum Dis, 69, 150, 10.1136/ard.2008.103739 · DOI
  22. Boschetti, 2015, Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohns disease., Inflamm Bowel Dis, 21, 331, 10.1097/MIB.0000000000000273 · DOI
  23. Cury, 2013, Serum calprotectin levels correlate with biochemical and histological markers of disease activity in TNBS colitis., Cell Immunol, 282, 66, 10.1016/j.cellimm.2013.04.004 · DOI
  24. Levine, 2011, Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification., Inflamm Bowel Dis, 17, 1314, 10.1002/ibd.21493 · DOI · Paper page
  25. Satsangi, 2006, The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications., Gut, 55, 749, 10.1136/gut.2005.082909 · DOI · Paper page
  26. Averill, 2012, S100A8 and S100A9 in cardiovascular biology and disease., Arterioscler Thromb Vasc Biol, 32, 223, 10.1161/ATVBAHA.111.236927 · DOI · Paper page
  27. Ingersoll, 2010, Comparison of gene expression profiles between human and mouse monocyte subsets., Blood, 115, e10, 10.1182/blood-2009-07-235028 · DOI · Paper page
  28. Fagerhol, 2005, Increase in plasma calprotectin during long-distance running., Scand J Clin Lab Invest, 65, 211, 10.1080/00365510510013587 · DOI · Paper page
  29. Leach, 2007, Serum and mucosal S100 proteins, calprotectin (S100A8S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease., Scand J Gastroenterol, 42, 1321, 10.1080/00365520701416709 · DOI · Paper page
  30. Hare, 2014, P349 Serum calprotectin: a novel biomarker to predict outcome in acute severe ulcerative colitis?, J Crohns Colitis, 8, S210, 10.1016/S1873-9946(14)60469-4 · doi:10.1016/s1873-9946(14)60469-4
  31. Mor, 2005, Serum protein markers for early detection of ovarian cancer., Proc Natl Acad Sci USA, 102, 7677, 10.1073/pnas.0502178102 · DOI · Paper page
  32. Xiao, 2005, An approach to studying lung cancer-related proteins in human blood., Mol Cell Proteomics, 4, 1480, 10.1074/mcp.M500055-MCP200 · DOI
  33. Kennedy, 2015, Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years., J Crohns Colitis, 9, 41
  34. Mosli, 2015, C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis., Am J Gastroenterol, 110, 802, 10.1038/ajg.2015.120 · DOI · Paper page
  35. af Bjorkesten, 2012, Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohns disease., Scand J Gastroenterol, 47, 528, 10.3109/00365521.2012.660542 · DOI · Paper page
  36. DHaens, 2012, Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease., Inflamm Bowel Dis, 18, 2218, 10.1002/ibd.22917 · DOI · Paper page
  37. Schoepfer, 2010, Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohns disease (SES-CD) than CRP, blood leukocytes, and the CDAI., Am J Gastroenterol, 105, 162, 10.1038/ajg.2009.545 · DOI · Paper page
  38. Langhorst, 2008, Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices., Am J Gastroenterol, 103, 162, 10.1111/j.1572-0241.2007.01556.x · DOI · Paper page
  39. Beaugerie, 2006, Predictors of crohns disease., Gastroenterology, 130, 650, 10.1053/j.gastro.2005.12.019 · DOI · Paper page
  40. Boirivant, 1988, The clinical significance of serum C reactive protein levels in Crohns disease. Results of a prospective longitudinal study., J Clin Gastroenterol, 10, 401, 10.1097/00004836-198808000-00011 · DOI · Paper page
  41. Niewiadomski, 2015, Prospective population-based cohort of inflammatory bowel disease in the biologics era: disease course and predictors of severity., J Gastroenterol Hepatol, 30, 1346, 10.1111/jgh.12967 · DOI
  42. Henriksen, 2008, C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study., Gut, 57, 1518, 10.1136/gut.2007.146357 · DOI · Paper page
  43. Sandor Kiss, 2012, High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohns disease: a marker for patient classification?, Inflamm Bowel Dis, 18, 1647, 10.1002/ibd.21933 · DOI
  44. Costa, 2005, Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohns disease., Gut, 54, 364, 10.1136/gut.2004.043406 · DOI · Paper page
  45. Henderson, 2015, Serum C-reactive protein and CRP genotype in pediatric inflammatory bowel disease: influence on phenotype, natural history, and response to therapy., Inflamm Bowel Dis, 21, 596, 10.1097/MIB.0000000000000296 · DOI

Cited by

Metadata

Authors
Kalla, R., Kennedy, N. A., Ventham, N. T., Boyapati, R. K., Adams, A. T., Nimmo, E. R., Visconti, M. R., Drummond, H., Ho, G.-T., Pattenden, R. J., Wilson, D. C., & Satsangi, J.
Venue
American Journal of Gastroenterology
Published
2016-12
Volume
111
Issue
12
Pages
1796-1805
ISSN
0002-9270 (ISSN-L)
OpenAlex
W2513920879
Cited by
124
References
2
FWCI
6.85
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.